GoCo Health Innovation City enters exciting next phase with approved development plan
Today, the vision of GoCo Health Innovation City took another step closer to becoming reality. With a recently approved development plan supported by the city of Mölndal, and a formal partnership between Next Step, Vectura, and AstraZeneca in place, GoCo Health Innovation City welcomed hundreds of participants to a launch event held today at the development site. Attendees learned about the new brand name, as well as what the ambitious project initiative aims to deliver.
“We are at an exciting crossroads right now in Sweden, in which we have the potential to be a true global leader in life science. The political will is there, and we already have numerous forward-thinking companies, organizations, and individuals based in Sweden,” said Matti Ahlqvist, AstraZeneca Gothenburg Site Director. “To take us to the next level, we need to create space for these different companies and perspectives to come together to collaborate and unlock new innovative ideas. That is exactly what GoCo Health Innovation City will do.”
GoCo Health Innovation City formally replaces prior names for the planned development site in Mölndal. As the name suggests, GoCo Health Innovation City has invited forward-thinking health companies, entrepreneurs, start-ups, academic experts, and designers to co-locate and collaborate. The GoCo Health Innovation City land will include the current AstraZeneca R&D site, as well as new buildings for new tenants. Opening in 2021, the first new building, designed by architectural partners Semrén & Månsson, will include a modular sustainable structure equipped with cutting-edge digital technology and collaborative environments.